Therapeutic vaccines; TNF-related inflammation
Research at Dr Jiang’s Laboratory focuses on understanding mechanisms of antigen presentation to the immune system; biomarker discovery and the development of new vaccines, including therapeutic vaccines with a particular emphasis on translating discoveries into new treatments for cancer patients. One major outcome of this work has been the development of a recombinant overlapping peptides technology for cancer therapeutic vaccines and diagnostics. This innovation has led to the formation of a spinout company, Oxford Vacmedix UK Ltd. Two candidates are close to clinical trials. Meanwhile the lab continues to focus on reaching an in-depth understanding of the immune pathways activated by ROPs and identifying additional targets that are amenable to the approach.
Another discovery at Dr Jiang’s Lab is a new biomarker, Inflammation Enhancer (IE). IE is an autoimmune disease factor - together with TNF, IE deteriorates inflammatory diseases such as sepsis and leads to high incidence of fatality. The lab is focusing on elucidating the pathway of IE that leads to inflammation. Diagnostic methods as well as treatments are also in development.
Alexander Stephens, DPhil Student
Yuqian Ou, Research Assistant
Rong Hu, Visiting Scholar
GROUP ALUMNI & NEXT DESTINATIONS
Sophie Owen - PhD Tropical Medicine, Liverpool School of Tropical Medicine, UK
Wenshu Lu - CEO, Shanghai Inflinhix Ltd
Neha Vashist-Postdoctoral Researcher, Würzburg, Bavaria, Germany
Jason Huang - Associate Medical Director, Oncology, Asia-Pacific at Merck Group, Singapore
Qiongyu Chen - USA
Hongwei Zhang - Associate Chief Physician, Beijing You'an Hospital, Capital Medical University, China
Hai Hong - Associate Professor, Sun Yat-Sen University, China